Join over 2,000 investors and sign up to our platform to review and compare our latest opportunities. Please contact us for more information about upcoming opportunities or our technology.
o2h Ventures Limited
About
"On our doorstep we have unbelievably good opportunities to invest. We can find great science and invest early, primarily because we can do quite detailed due diligence due to our background in life sciences."
Sunil Shah, CEO, o2h Ventures LtdInvestment focus
Key team members
Sunil Shah is a serial entrepreneur having begun his career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. Sunil is the CEO of the o2h Group. The o2h Group has developed an engine for seeding a pipeline of early stage life science assets through research collaborations, in-licensing, spin-outs & investments. The DNA of o2h is centred around the nurturing of its people, values and culture, it reflects in the way we work with each other, as well as our collaborators and partners.
Sunil was awarded Angel of the Year 2019 by UKBAA for his active participation in backing high growth potential startups and early-stage businesses in the UK as well as the OBN Special Recognition Award for his signification contribution in the Life Sciences Industry. He is a Board Director of Cambridge Angels and also is a member of the Advisory Panel of Cancer Research UK (CRUK) which is the UK’s largest cancer research charity. He is either Chairman, Director, Board Observer or investor of: Phoremost, Exonate, Opal Oncology, Five Alarm Bio, Somaserve, DeepMatter, Oppilotech, Sentinel, Small Pharma, Arecor, Metrion, Talisman, Stemnovate, Acacia, Privitar and Oxford Drug Design.
A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management.
Andy is a medicinal chemist with over 25 years working in major pharma (Sanofi-Aventis, AZ). He has experience across all discovery phases, having supported five candidates into the clinic. He is an author and inventor of over 55 publications and patents. He has been working with the o2h group since 2013 to lead the scientific evaluation of the investments and also provides scientific support on key projects within the portfolio. He is the CSO of Opal Oncology and effective CSO for two o2h earlystage collaborations.
Investment opportunities
We are working to make investments from this manager available on our platform.
Investment opportunities are added daily, please check back soon.